{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:55Z","timestamp":1790876695291,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"DOI":"10.7759\/cureus.100953","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T01:51:41Z","timestamp":1767750701000},"source":"Crossref","is-referenced-by-count":1,"title":["Sight Unseen: Glucagon-Like Peptide-1 (GLP-1) Agonism Therapy and Nonarteritic Anterior Ischemic Optic Neuropathy"],"prefix":"10.7759","author":[{"given":"Maxim J","family":"Barnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Festus","family":"Ibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.694284","article-title":"What is an L-cell and how do we study the secretory mechanisms of the L-cell?","volume":"12","author":"Kuhre RE","year":"2021","unstructured":"Kuhre RE, Deacon CF, Holst JJ, Petersen N. What is an L-cell and how do we study the secretory mechanisms of the L-cell?. Front Endocrinol (Lausanne). 2021, 12:694284. 10.3389\/fendo.2021.694284","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00260","article-title":"From the incretin concept and the discovery of GLP-1 to today's diabetes therapy","volume":"10","author":"Holst JJ","year":"2019","unstructured":"Holst JJ. From the incretin concept and the discovery of GLP-1 to today's diabetes therapy. Front Endocrinol (Lausanne). 2019, 10:260. 10.3389\/fendo.2019.00260","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2017.22.1.15","article-title":"Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes","volume":"22","author":"Lee S","year":"2017","unstructured":"Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab. 2017, 22:15-26. 10.6065\/apem.2017.22.1.15","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff AM","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023, 389:514-26. 10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102214","article-title":"The expanding benefits of GLP-1 medicines","volume":"6","author":"Gonzalez-Rellan MJ","year":"2025","unstructured":"Gonzalez-Rellan MJ, Drucker DJ. The expanding benefits of GLP-1 medicines. Cell Rep Med. 2025, 6:102214. 10.1016\/j.xcrm.2025.102214","journal-title":"Cell Rep Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03718-0","article-title":"Are synthetic incretins associated with ischaemic optic neuropathy?","volume":"39","author":"Gregory V","year":"2025","unstructured":"Gregory V, Mollan SP. Are synthetic incretins associated with ischaemic optic neuropathy?. Eye (Lond). 2025, 39:808-9. 10.1038\/s41433-025-03718-0","journal-title":"Eye (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide","volume":"143","author":"Katz BJ","year":"2025","unstructured":"Katz BJ, Lee MS, Lincoff NS, et al.. Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide. JAMA Ophthalmol. 2025, 143:215-20. 10.1001\/jamaophthalmol.2024.6058","journal-title":"JAMA Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway JT","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, et al.. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024, 142:732-9. 10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.26502\/aimr.0189","article-title":"Semaglutide: double-edged sword with risks and benefits","volume":"8","author":"Pillarisetti L","year":"2025","unstructured":"Pillarisetti L, Agrawal DK. Semaglutide: double-edged sword with risks and benefits. Arch Intern Med Res. 2025, 8:1-13. 10.26502\/aimr.0189","journal-title":"Arch Intern Med Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund J","year":"2024","unstructured":"Grauslund J, Taha AA, Molander LD, Kawasaki R, M\u00f6ller S, H\u00f8jlund K, Stokholm L. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024, 10:97. 10.1186\/s40942-024-00620-x","journal-title":"Int J Retina Vitreous"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/01658107.2024.2411260","article-title":"Bilateral non-arteritic anterior ischemic optic neuropathy following weight loss from semaglutide (Ozempic): a case report","volume":"49","author":"Karam EZ","year":"2024","unstructured":"Karam EZ, Johnson N, Sensenbrenner S. Bilateral non-arteritic anterior ischemic optic neuropathy following weight loss from semaglutide (Ozempic): a case report. Neuro-Ophthalmol. 2024, 49:313-9. 10.1080\/01658107.2024.2411260","journal-title":"Neuro-Ophthalmol"},{"key":"ref12","article-title":"Non-arteritic ischemic optic neuropathy in patients receiving a glucagon-like peptide receptor agonist in a tertiary care center","volume":"65","author":"Carreno-Galeano JT","year":"2024","unstructured":"Carreno-Galeano JT, Shah M, Zekavat SM, Krasniqi D, Hathaway DB, Rizzo JF. Non-arteritic ischemic optic neuropathy in patients receiving a glucagon-like peptide receptor agonist in a tertiary care center. Invest Ophthalmol Visc Sci. 2024, 65:","journal-title":"Invest Ophthalmol Visc Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen E","year":"2025","unstructured":"Simonsen E, Lund LC, Ernst MT, et al.. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study. Diabetes Obes Metab. 2025, 27:3094-103. 10.1111\/dom.16316","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Chou CC","year":"2025","unstructured":"Chou CC, Pan SY, Sheen YJ, et al.. Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study. Ophthalmology. 2025, 132:381-8. 10.1016\/j.ophtha.2024.10.030","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai CX","year":"2025","unstructured":"Cai CX, Hribar M, Baxter S, et al.. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025, 143:304-14. 10.1001\/jamaophthalmol.2024.6555","journal-title":"JAMA Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","volume":"143","author":"Hsu AY","year":"2025","unstructured":"Hsu AY, Kuo HT, Wang YH, et al.. Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes. JAMA Ophthalmol. 2025, 143:400-7. 10.1001\/jamaophthalmol.2025.0349","journal-title":"JAMA Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani M","year":"2025","unstructured":"Lakhani M, Kwan AT, Mihalache A, et al.. Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries. Am J Ophthalmol. 2025, 277:148-68. 10.1016\/j.ajo.2025.05.007","journal-title":"Am J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2025.03.001","article-title":"Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: an emerging pharmacovigilance signal?","volume":"19","author":"Procacci A","year":"2025","unstructured":"Procacci A, Poluzzi E, De Ponti F, Raschi E. Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: an emerging pharmacovigilance signal?. Obes Res Clin Pract. 2025, 19:178-80. 10.1016\/j.orcp.2025.03.001","journal-title":"Obes Res Clin Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system - a disproportionality analysis","volume":"19","author":"Azab M","year":"2025","unstructured":"Azab M, Pasina L. Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system - a disproportionality analysis. Obes Res Clin Pract. 2025, 19:77-9. 10.1016\/j.orcp.2025.01.011","journal-title":"Obes Res Clin Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass NJ","year":"2025","unstructured":"Abbass NJ, Nahlawi R, Shaia JK, Allan KC, Kaelber DC, Talcott KE, Singh RP. The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 2025, 274:24-31. 10.1016\/j.ajo.2025.02.025","journal-title":"Am J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000212637","article-title":"Risk of non-arteritic anterior ischemic optic neuropathy in patients with type 2 diabetes and obesity using GLP-1 receptor agonists: a cohort study","volume":"104","author":"Andre\u00e3o F","year":"2025","unstructured":"Andre\u00e3o F, Amaral D, Louzada R, Monteiro M, Santos DH. Risk of non-arteritic anterior ischemic optic neuropathy in patients with type 2 diabetes and obesity using GLP-1 receptor agonists: a cohort study. Neurology. 2025, 104:7. 10.1212\/WNL.0000000000212637","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.05.011","article-title":"Nonarteritic anterior ischemic optic neuropathy and glucagon-like peptide-1 receptor agonists: evaluating a potential association","volume":"140","author":"\u00d6zbek L","year":"2025","unstructured":"\u00d6zbek L, G\u00fcldan M, Fidan DG, Abdel-Rahman SM, Kanbay M. Nonarteritic anterior ischemic optic neuropathy and glucagon-like peptide-1 receptor agonists: evaluating a potential association. Eur J Intern Med. 2025, 140:106346. 10.1016\/j.ejim.2025.05.011","journal-title":"Eur J Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials","volume":"27","author":"Silverii GA","year":"2025","unstructured":"Silverii GA, Pala L, Cresci B, Mannucci E. Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2025, 27:1005-9. 10.1111\/dom.16076","journal-title":"Diabetes Obes Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241268050","article-title":"Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff DC","year":"2024","unstructured":"Klonoff DC, Hui G, Gombar S. Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. J Diabetes Sci Technol. 2024, 18:1517-8. 10.1177\/19322968241268050","journal-title":"J Diabetes Sci Technol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes","volume":"8","author":"Wang L","year":"2025","unstructured":"Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025, 8:e2526327. 10.1001\/jamanetworkopen.2025.26327","journal-title":"JAMA Netw Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes","volume":"8","author":"Ramsey DJ","year":"2025","unstructured":"Ramsey DJ, Makwana B, Dani SS, et al.. GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes. JAMA Netw Open. 2025, 8:e2526321. 10.1001\/jamanetworkopen.2025.26321","journal-title":"JAMA Netw Open"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.2332","article-title":"GLP-1RA exposure and nonarteritic anterior ischemic optic neuropathy prevalence by diabetes status","volume":"143","author":"Nagdeve P","year":"2025","unstructured":"Nagdeve P, Griffin R. GLP-1RA exposure and nonarteritic anterior ischemic optic neuropathy prevalence by diabetes status. JAMA Ophthalmol. 2025, 143:792-5. 10.1001\/jamaophthalmol.2025.2332","journal-title":"JAMA Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.2489","article-title":"Ocular adverse events with semaglutide: a systematic review and meta-analysis","volume":"143","author":"Natividade GR","year":"2025","unstructured":"Natividade GR, Spiazzi BF, Baumgarten MW, et al.. Ocular adverse events with semaglutide: a systematic review and meta-analysis. JAMA Ophthalmol. 2025, 143:759-68. 10.1001\/jamaophthalmol.2025.2489","journal-title":"JAMA Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.33696\/cardiology.6.068","article-title":"Semaglutide-inducing non-arteritic anterior ischemic optic neuropathy and ipsilateral blindness - a rare presentation","volume":"6","author":"Mao B","year":"2025","unstructured":"Mao B, Goberdhan S, Mumtaz U, Tahir S, Hussain ST. Semaglutide-inducing non-arteritic anterior ischemic optic neuropathy and ipsilateral blindness - a rare presentation. J Clin Cardiol. 2025, 6:33-6. 10.33696\/cardiology.6.068","journal-title":"J Clin Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-03958-4","article-title":"Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association","volume":"25","author":"Ahmadi H","year":"2025","unstructured":"Ahmadi H, Hamann S. Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association. BMC Ophthalmol. 2025, 25:132. 10.1186\/s12886-025-03958-4","journal-title":"BMC Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S531930","article-title":"Non-arteritic anterior ischemic optic neuropathy in an otherwise healthy young adult patient treated with liraglutide and semaglutide for weight loss: a cautionary tale","volume":"18","author":"Lixi F","year":"2025","unstructured":"Lixi F, Calabresi V, Cukurova F, Giannaccare G. Non-arteritic anterior ischemic optic neuropathy in an otherwise healthy young adult patient treated with liraglutide and semaglutide for weight loss: a cautionary tale. Int Med Case Rep J. 2025, 18:991-5. 10.2147\/IMCRJ.S531930","journal-title":"Int Med Case Rep J"},{"key":"ref32","unstructured":"Curtain-like Vision Loss. A Case Report on Semaglutide and its Effects on Vision. (2025). Accessed: September 9, 2025: https:\/\/scholarlycommons.hcahealthcare.com\/northtexas2025\/106\/."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/11206721251331655","article-title":"Non arteritic ischemic optic neuropathy in a patient taking semaglutide: is there a relation? A case report and a review of the literature","volume":"35","author":"Maceroni M","year":"2025","unstructured":"Maceroni M, Sasso P, Giarletti M, Bruno V, Minnella AM. Non arteritic ischemic optic neuropathy in a patient taking semaglutide: is there a relation? A case report and a review of the literature. Eur J Ophthalmol. 2025, 35:NP10-5. 10.1177\/11206721251331655","journal-title":"Eur J Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/reports8030149","article-title":"Is semaglutide linked to NAION? A case report on a rare ocular complication","volume":"8","author":"Le\u0161in Ga\u0107ina D","year":"2025","unstructured":"Le\u0161in Ga\u0107ina D, Vidovi\u0107 T, Vlaji\u0107 Oreb N, Matkovi\u0107 L, Jandrokovi\u0107 S. Is semaglutide linked to NAION? A case report on a rare ocular complication. Reports (MDPI). 2025, 8:9. 10.3390\/reports8030149","journal-title":"Reports (MDPI)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4103\/aian.aian_533_22","article-title":"Ischemic optic neuropathies: current concepts","volume":"25","author":"Patil AD","year":"2022","unstructured":"Patil AD, Biousse V, Newman NJ. Ischemic optic neuropathies: current concepts. Ann Indian Acad Neurol. 2022, 25:S54-8. 10.4103\/aian.aian_533_22","journal-title":"Ann Indian Acad Neurol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1413352","article-title":"Ischemic optic neuropathies","volume":"372","author":"Biousse V","year":"2015","unstructured":"Biousse V, Newman NJ. Ischemic optic neuropathies. N Engl J Med. 2015, 372:2428-36. 10.1056\/NEJMra1413352","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-025-07831-7","article-title":"Broadening horizons with GLP-1 receptor analogues as an adjunct to bariatric metabolic surgery: risk awareness of a possible link to non-arteritic ischemic optic neuropathy","volume":"35","author":"Varughese MS","year":"2025","unstructured":"Varughese MS, Kalidindi S. Broadening horizons with GLP-1 receptor analogues as an adjunct to bariatric metabolic surgery: risk awareness of a possible link to non-arteritic ischemic optic neuropathy. Obes Surg. 2025, 35:1968-70. 10.1007\/s11695-025-07831-7","journal-title":"Obes Surg"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.618353","article-title":"Risk factors for non-arteritic anterior ischemic optic neuropathy: a large-scale meta-analysis","volume":"8","author":"Liu B","year":"2021","unstructured":"Liu B, Yu Y, Liu W, Deng T, Xiang D. Risk factors for non-arteritic anterior ischemic optic neuropathy: a large-scale meta-analysis. Front Med (Lausanne). 2021, 8:618353. 10.3389\/fmed.2021.618353","journal-title":"Front Med (Lausanne)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/vision7040072","article-title":"Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview","volume":"7","author":"Salvetat ML","year":"2023","unstructured":"Salvetat ML, Pellegrini F, Spadea L, Salati C, Zeppieri M. Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview. Vision (Basel). 2023, 7:2. 10.3390\/vision7040072","journal-title":"Vision (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101664","article-title":"What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes","volume":"51","author":"Feldman-Billard S","year":"2025","unstructured":"Feldman-Billard S. What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes. Diabetes Metab. 2025, 51:101664. 10.1016\/j.diabet.2025.101664","journal-title":"Diabetes Metab"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S125311","article-title":"Nonarteritic anterior ischemic optic neuropathy: cause, effect, and management","volume":"9","author":"Berry S","year":"2017","unstructured":"Berry S, Lin WV, Sadaka A, Lee AG. Nonarteritic anterior ischemic optic neuropathy: cause, effect, and management. Eye Brain. 2017, 9:23-8. 10.2147\/EB.S125311","journal-title":"Eye Brain"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.144","article-title":"Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy","volume":"29","author":"Miller NR","year":"2015","unstructured":"Miller NR, Arnold AC. Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy. Eye (Lond). 2015, 29:65-79. 10.1038\/eye.2014.144","journal-title":"Eye (Lond)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v15.i3.311","article-title":"Acute worsening of microvascular complications of diabetes mellitus during rapid glycemic control: the pathobiology and therapeutic implications","volume":"15","author":"Blaibel D","year":"2024","unstructured":"Blaibel D, Fernandez CJ, Pappachan JM. Acute worsening of microvascular complications of diabetes mellitus during rapid glycemic control: the pathobiology and therapeutic implications. World J Diabetes. 2024, 15:311-7. 10.4239\/wjd.v15.i3.311","journal-title":"World J Diabetes"},{"key":"ref44","unstructured":"American Academy of Ophthalmology. Weight-Loss Drug and Eye Health. (2025). Accessed. July 12, 2025: https:\/\/www.aao.org\/newsroom\/news-releases\/detail\/weight-loss-drug-and-eye-health."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0241","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee MM","year":"2025","unstructured":"Lee MM, Sattar N, Pop-Busui R, et al.. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care. 2025, 48:846-59. 10.2337\/dc25-0241","journal-title":"Diabetes Care"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa082","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Marsico F","year":"2020","unstructured":"Marsico F, Paolillo S, Gargiulo P, et al.. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020, 41:3346-58. 10.1093\/eurheartj\/ehaa082","journal-title":"Eur Heart J"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad076","article-title":"GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"108","author":"Banerjee M","year":"2023","unstructured":"Banerjee M, Pal R, Mukhopadhyay S, Nair K. GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2023, 108:1806-12. 10.1210\/clinem\/dgad076","journal-title":"J Clin Endocrinol Metab"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen S","year":"2019","unstructured":"Kristensen S, R\u00f8rth R, Jhund PS, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019, 7:776-85. 10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2021.05.043","article-title":"Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus","volume":"154","author":"Grewal S","year":"2021","unstructured":"Grewal S, Zaman N, Borgatta L, Nudy M, Foy AJ, Peterson B. Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus. Am J Cardiol. 2021, 154:48-53. 10.1016\/j.amjcard.2021.05.043","journal-title":"Am J Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16476","article-title":"Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: a systematic review and meta-analysis","volume":"27","author":"Alammari N","year":"2025","unstructured":"Alammari N, Alshehri A, Al Khalaf A, et al.. Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: a systematic review and meta-analysis. Diabetes Obes Metab. 2025, 27:4387-400. 10.1111\/dom.16476","journal-title":"Diabetes Obes Metab"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.7326\/M23-1490","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American College of Physicians","volume":"177","author":"Drake T","year":"2024","unstructured":"Drake T, Landsteiner A, Langsetmo L, et al.. Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med. 2024, 177:618-32. 10.7326\/M23-1490","journal-title":"Ann Intern Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano D","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, et al.. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021, 20:189. 10.1186\/s12933-021-01366-8","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450929-sight-unseen-glucagon-like-peptide-1-glp-1-agonism-therapy-and-nonarteritic-anterior-ischemic-optic-neuropathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T01:51:44Z","timestamp":1767750704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450929-sight-unseen-glucagon-like-peptide-1-glp-1-agonism-therapy-and-nonarteritic-anterior-ischemic-optic-neuropathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":52,"URL":"https:\/\/doi.org\/10.7759\/cureus.100953","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}